Abstract: The present disclosure provides a diabetes mellitus therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a therapy for diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus, said therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a diagnosis of diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus or a risk of the same, said diagnosis using abnormal stem cells as an index. In one embodiment, the abnormal stem cells described in the present disclosure are abnormal hematopoietic stem cells. In one embodiment, CD106 is expressed in the abnormal stem cells described in the present disclosure at a level different from in normal cells.

Abstract: The present disclosure provides a therapy for diabetes that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides diagnosis of diabetes and/or diabetes-related diseases and disorders and/or symptoms, or the risk thereof, using abnormal stem cell migration and/or residence as an indicator.

Abstract: An optical connection detecting device has in a front face thereof a light emission display portion for detecting an optical connection, and in both front and rear ends of a lower face thereof a switch lever for detecting the optical connection. In an optical adapter, ferrule leading end portions of optical connector plugs inserted from fitting portions in both ends are butt jointed, leading ends of the switch levers in both front and rear ends of the optical connection detecting device are faced to notch concave portions which are formed in upper wall sides of opening ends of both the fitting portions of the optical adapter. When the optical connector plug is fully inserted into the fitting portion of the optical adapter instead of being in a half-inserted state, the switch lever is pushed up and the light emission display portion is displayed with an on-state lighting color.

Abstract: An optical connection detecting device has in a front face thereof a light emission display portion for detecting an optical connection, and in both front and rear ends of a lower face thereof a switch lever for detecting the optical connection. In an optical adapter, ferrule leading end portions of optical connector plugs inserted from fitting portions in both ends are butt jointed, leading ends of the switch levers in both front and rear ends of the optical connection detecting device are faced to notch concave portions which are formed in upper wall sides of opening ends of both the fitting portions of the optical adapter. When the optical connector plug is fully inserted into the fitting portion of the optical adapter instead of being in a half-inserted state, the switch lever is pushed up and the light emission display portion is displayed with an on-state lighting color.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: For easy operation under a high density mounting circumstance, a multiple type optical connector plug to be connected with an optical adapter formed via a partition wall provided in a plural branch structured module, is provided with canceling levers (11), each including locking pieces (12) for engaging with the adapter and locking pieces (11a) on a rear end portion, on one surface in a longitudinal direction of a plug main body (1) from a front side toward a rear side, and a slider (13) movably attached to regulation regions in an axial direction of the plug main bodies (1) via a holder portion which is divided into upper and lower portions (19a, 19b) for incorporating plug main bodies (1), and the slider (13) has cam portions (13a) which engage with the canceling pieces (11a) on each of the canceling levers (11) so as to be capable of pressing them.